Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab

Dupilumab efficacy in patients with ABPA and asthma has previously been reported in single case reports. 3,4 A post hoc analysis of the LIBERTY trial also showed reduced exacerbations in 18 participants treated with dupilumab who had serologic markers suggestive of ABPA but no formal diagnosis. 5 Ou...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical and translational allergy 2021-12, Vol.11 (10), p.e12081-n/a
Main Authors:	Veer, Tjeerd, Dallinga, Marloes A., Valk, Johanna P. M., Kappen, Jasper H., in ’t Veen, Johannes C. C. M., Eerden, Menno M., Braunstahl, Gert‐Jan
Format:	Article
Language:	eng
Subjects:	ABPA allergic bronchopulmonary aspergillosis allergische bronchopulmonale aspergillose asma Aspergilosis broncopulmonar alérgica Asthma Conflicts of interest dupilumab Letter Patients Steroids
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Dupilumab efficacy in patients with ABPA and asthma has previously been reported in single case reports. 3,4 A post hoc analysis of the LIBERTY trial also showed reduced exacerbations in 18 participants treated with dupilumab who had serologic markers suggestive of ABPA but no formal diagnosis. 5 Our retrospective case series approved by the institutional review board presents eight patients with allergic asthma as well as ABPA diagnosed by a pulmonologist according to the diagnostic criteria of the International Society for Human and Animal Mycology. 1 All patients provided written informed consent for data collection. TABLE 1 Patients characteristics and parameters at baseline, before and after starting dupilumab treatment Parameter Number of exacerbations Prednisone maintenance dose (mg/day) FEV1 %pred Total IgE kU/L Serum eosinophils (absolute × 109/L) Patient sex, age During 6 months before start dupilumab During 6 months after start dupilumab Base line After 6 months Base line After 6 months Base line After 6 months Base line After 6 months 1. [...]based on this case series and strong immunological arguments, dupilumab seems to have strong beneficial clinical effects on the number of exacerbations and prednisone maintenance dose in asthmatic patients with a diagnosis of ABPA.
ISSN:	2045-7022 2045-7022